ArticleFrontiers in pharmacology2025
The effect of Zuogui-Jiangtang-Yishen decoction on the intestinal flora's response to L-α-phosphatidylcholine and L-tyrosine in patients with diabetic kidney disease: an
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting PSAT1 in diabetic kidney disease: a ferroptosis-driven strategy for precision therapy.Molecular and cellular biochemistry · 2026Article
- Focus on gut microbiota regulation: exploring the potential of fermented traditional Chinese medicines in the prevention and treatment of type 2 diabetes mellitus.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Animal and cell studies have demonstrated that Zuogui-Jiangtang-Yishen decoction (ZGJTYS) has a favorable effect on the treatment of diabetic kidney disease (DKD). Our previous clinical research also showed that ZGJTYS prevents DKD in a manner similar to that of benazepril. Nevertheless, the interactions between ZGJTYS and the human gut microbiota require further investigation, particularly its interference in the intestinal flora response to food ingredients that may increase DKD risk, such as L-α-phosphatidylcholine and L-tyrosine. Objective: The aim of this study was to evaluate the regulatory function of ZGJTYS on human gut microbiota and explore the effect of ZGJTYS on the intestinal flora response to L-α-phosphatidylcholine and L-tyrosine. Methods: ZGJTYS was prescribed from the First Affiliated Hospital of Hunan University of Chinese Medicine. High-throughput sequencing of bacterial 16S RNA genes and fungal internal transcribed spacer (ITS) sequences was used for intestinal flora analysis. An Results: Compared to the control group, the microbial diversity of DKD was significantly reduced by ZGJTYS treatment; three bacterial genera, including Conclusion: ZGJTYS was found to effectively restore the microbiota that were altered by L-α-phosphatidylcholine and L-tyrosine to normal, along with their metabolites. However, the mechanism by which ZGJTYS exerts its preventive and therapeutic effects on DKD through the gut microbiota still requires further study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.